Literature DB >> 6363079

Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial.

S P Hanley, J R Hampton.   

Abstract

Twenty-four patients received either propranolol, lidoflazine (Clinium), or propranolol/lidoflazine combinations in a study designed to evaluate the effect of these drugs in angina pectoris. Five patients developed ventricular tachycardia when receiving either lidoflazine or lidoflazine and propranolol in combination; one of these patients died. In addition, one patient died suddenly while being treated with propranolol alone. Lidoflazine therapy was associated with a significant prolongation of the QT interval of the electrocardiogram. Lidoflazine either alone or in combination with propranolol, appears to induce ventricular tachycardia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6363079     DOI: 10.1093/oxfordjournals.eurheartj.a061417

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

1.  Effects on infarct size of reperfusion and pretreatment with beta-blockade and calcium antagonists.

Authors:  S Torr; A J Drake-Holland; M Main; J Hynd; K Isted; M I Noble
Journal:  Basic Res Cardiol       Date:  1989 Nov-Dec       Impact factor: 17.165

Review 2.  Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 3.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 4.  Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

5.  A comparison of the effects of a series of anti-anginal agents in a novel canine model of transient myocardial ischaemia.

Authors:  M C Allely; B J Alps
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

Review 6.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18

Review 7.  Toward a broader view of mechanisms of drug cardiotoxicity.

Authors:  Polina Mamoshina; Blanca Rodriguez; Alfonso Bueno-Orovio
Journal:  Cell Rep Med       Date:  2021-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.